These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24946955)

  • 1. Targeting of gut specific leucocyte recruitment in IBD by vedolizumab.
    Eksteen B
    Gut; 2015 Jan; 64(1):8-10. PubMed ID: 24946955
    [No Abstract]   [Full Text] [Related]  

  • 2. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
    Wyant T; Leach T; Sankoh S; Wang Y; Paolino J; Pasetti MF; Feagan BG; Parikh A
    Gut; 2015 Jan; 64(1):77-83. PubMed ID: 24763133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.
    Fedyk ER; Wyant T; Yang LL; Csizmadia V; Burke K; Yang H; Kadambi VJ
    Inflamm Bowel Dis; 2012 Nov; 18(11):2107-19. PubMed ID: 22419649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
    Milch C; Wyant T; Xu J; Parikh A; Kent W; Fox I; Berger J
    J Neuroimmunol; 2013 Nov; 264(1-2):123-6. PubMed ID: 24067534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
    Ghosh N; Chaki R; Mandal SC
    Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
    Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
    Rosario M; Dirks NL; Milch C; Parikh A; Bargfrede M; Wyant T; Fedyk E; Fox I
    Clin Pharmacokinet; 2017 Nov; 56(11):1287-1301. PubMed ID: 28523450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
    Poulakos M; Machin JD; Pauly J; Grace Y
    J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
    Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
    Zundler S; Neurath MF
    Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New molecules in the treatment of inflammatory bowel disease].
    Chaparro M; Gisbert JP
    Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vedolizumab (Entyvio®) for the treatment of inflammatory bowel diseases].
    Van Kemseke C; Louis E; Reenaers C
    Rev Med Liege; 2015 Nov; 70(11):575-82. PubMed ID: 26738270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
    Pijls PA; Gilissen LP
    Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.